title: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.
abstract: BACKGROUND
  A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific PSMA peptides (PSM-P1 and -P2). This report describes thirty three subjects with hormone-refractory metastatic prostate cancer without prior vaccine therapy history who were evaluated and reported as a group.
  
  
  METHODS
  All subjects received six infusions of DC pulsed with PSM-P1 and -P2 at six week intervals. Clinical monitoring was conducted pre-, during, and post- phase II study. Data collected include: complete blood count, bone and total alkaline phosphatase, prostate markers, physical examination, performance status, bone scan, ProstaScint scan, chest x-ray, as well as assays to monitor cellular immune responses.
  
  
  RESULTS
  Six partial and two complete responders were identified in the phase II study based on NPCP criteria, plus 50% reduction of prostate-specific antigen (PSA), or resolution in previously measurable lesions on ProstaScint scan.
  
  
  CONCLUSIONS
  Over 30% of study participants in this group showed a positive response at the conclusion of the trial. This study suggested that DC-based cancer vaccines may provide an alternative therapy for prostate cancer patients whose disease no longer responds to hormone therapy.
authors.affiliation: Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, Washington 98125, USA.
authors.forename: G P
authors.initials: GP
authors.lastname: Murphy
authors.forename: B A
authors.initials: BA
authors.lastname: Tjoa
authors.forename: S J
authors.initials: SJ
authors.lastname: Simmons
authors.forename: J
authors.initials: J
authors.lastname: Jarisch
authors.forename: V A
authors.initials: VA
authors.lastname: Bowes
authors.forename: H
authors.initials: H
authors.lastname: Ragde
authors.forename: M
authors.initials: M
authors.lastname: Rogers
authors.forename: A
authors.initials: A
authors.lastname: Elgamal
authors.forename: G M
authors.initials: GM
authors.lastname: Kenny
authors.forename: O E
authors.initials: OE
authors.lastname: Cobb
authors.forename: R C
authors.initials: RC
authors.lastname: Ireton
authors.forename: M J
authors.initials: MJ
authors.lastname: Troychak
authors.forename: M L
authors.initials: ML
authors.lastname: Salgaller
authors.forename: A L
authors.initials: AL
authors.lastname: Boynton
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000627:therapeutic use; D000954:Antigens, Surface; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D002268:Carboxypeptidases / Q000008:administration & dosage / Q000627:therapeutic use*; D003713:Dendritic Cells; D043425:Glutamate Carboxypeptidase II; D015789:HLA-A2 Antigen / Q000008:administration & dosage / Q000627:therapeutic use*; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011877:Radionuclide Imaging; D016896:Treatment Outcome; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*